Now could be the time to buy the ASX 200 stock in this article.

That’s because the team at Bell Potter has just reaffirmed its buy rating on the stock.

Which ASX 200 stock?

The stock that is getting attention from Bell Potter is agricultural chemicals company Nufarm Ltd (ASX: NUF).

Bell Potter points out that recent peer reporting highlights continued margin recovery and trade flows suggesting a solid level of inventory rebuild ahead of major selling windows. It said: 

Key highlights from reporting season include: (1) Average reported selling prices were down -2% YoY and volumes were down -2% YoY; and (2) Gross margins (where reported) were up +180bp YoY. Like recent quarters, peer results continue to imply FY26e is a year of margin recover (as lower inventory moves through COGS) more so than top line growth.

Sector trade flows demonstrated -were down -3% YoY in volume terms and were down -18% YoY in value terms in 3Q26. The YoY change in sell through was stronger than the refill in value terms, implying formulators have not restocked with expensive stock, noting the volatility in China actives in the quarter

It also highlights that omega-3 oil pricing indicators have been firm. The broker adds:

Pricing indicators for omega-3 oil have remained firm and at levels consistent with previous peak pricing levels. South American fishoil prices are up +70-180% from Mar’26 levels, with bulk fishoil (the product most comparable to NUF Omega-3 products) last trading at US$4,650-8,250/t.

Time to buy

According to the note, Bell Potter has retained its buy rating on the ASX 200 stock with an improved price target of $3.75 (from $3.60).

Based on its current share price of $3.29, this implies potential upside of 14% for investors over the next 12 months. A 1% dividend yield is also expected over the period.

Commenting on its buy recommendation, Bell Potter said:

Our Buy rating is unchanged. Trading trends continue to infer FY26e is a year where improved gross margin (on lower COGS) and cost out are the main driver of profit growth. The[re] is the potential for surprise is omega-3, where Peruvian fishoil stock is in short supply and pricing indicators are reaching levels consistent with previous peaks.

There are modest EBITDA changes (<-1%) largely reflecting FX mark-to market. Our target price lifts to $3.75ps (prev. $3.60ps) on model roll forward.

The post Bell Potter says this ASX 200 stock is a buy appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Thursday

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Pro Medicus Ltd (ASX: PME) shares may be the single best thing an ordinary Australian investor could have owned over the past decade.

The medical imaging software company was a modest small-cap in 2016.

It is now a business worth close to $18 billion.

The share price has fallen 39% over the past twelve months, however, this hasn’t seemed to have impacted the long-term picture much.

Here is exactly what $10,000 would have become.

The maths on Pro Medicus shares over a decade

Pro Medicus shares traded at roughly $5.00 a share through the second half of 2016.

A $10,000 investment would have bought around 2,000 shares.

Those shares closed on Tuesday at $173.15.

The initial investment is now worth approximately $346,000. That is a gain of close to 3,360% before dividends.

Speaking of, dividends improve the number again.

Pro Medicus has paid a fully franked dividend across the entire period.

To illustrate, the FY26 payout alone came to 69 cents per share.

Measured against the original $5.00 purchase price, that single year of income represents almost 14% of what the investor paid back in 2016.

What actually drove the returns

The business did the work, not the market.

Visage is the platform radiologists use to view, store and share medical images.

The platform wins long contracts with large North American hospital networks, and it keeps them.

Revenue has compounded relentlessly while margins widened as the company scaled.

That combination is rare anywhere on the ASX and close to non-existent in healthcare.

Inside the FY26 result

FY26 was another strong year by almost any measure.

Revenue rose 22.9% to $261.7 million and underlying EBIT climbed 24.4% to $196.1 million.

Underlying net profit after tax increased 24.1% to $144.7 million.

Reported net profit jumped 130.3% to $265.3 million.

The company signed ten new contracts worth more than $407 million, including a ten-year agreement with UC Health Colorado.

Six existing contracts were renewed on five-year terms at higher fees.

Cash and financial assets grew 19.7% to $252.3 million, and the balance sheet still carries no debt at all.

Chief executive Dr Sam Hupert was satisfied with how the year finished.

We were aiming for 30% increases in EBIT and NPAT, and we exceeded both on a constant currency basis.

Why Pro Medicus shares have fallen 40% anyway

None of that stopped the share price falling hard.

Pro Medicus shares have dropped from a 52-week high of $321.57 to $173.15. The stock still trades on a price-to-earnings ratio of roughly 67.

That is a high multiple, and it leaves no room for a slower quarter of contract announcements.

Anyone who bought at the high is down more than 45%, which shows how important timing can be.

The valuation question facing new buyers

Buying a wonderful business at any price is not a strategy.

Pro Medicus needs to keep growing near 25% a year to justify what the market pays for it.

The addressable market in North American radiology is large, though it is not infinite.

Competition from larger imaging vendors is there, and contract timing is lumpy by nature.

Foolish takeaway

A $10,000 parcel bought a decade ago is worth around $346,000 today, not including dividends, which is a life-changing outcome from a very ordinary sum of money.

The lesson is not that Pro Medicus shares were an obvious buy in 2016, because they were nothing of the sort.

I would not chase the stock at 67 times earnings today.

But I would also not sell away a decade of compounding simply because the share price has had a difficult twelve months.

The post How much would $10,000 invested 10 years ago in Pro Medicus shares be worth today? appeared first on The Motley Fool Australia.

More reading

• Want to invest in AI shares? Here’s how to do it on the ASX
• Where I’d invest $20,000 in ASX shares this spring
• How much could the Pro Medicus share price rise in the next year?
• Warren Buffett’s playbook: 3 cheap ASX shares that could soar up to 60%
• 3 ASX shares I’d buy for the next 15 years

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The good news for investors is that passive income does not have to come only from picking individual dividend shares.

ASX exchange traded funds (ETFs) can also be used to build an income stream, while spreading money across a portfolio of different holdings.

That can make them a handy option for investors who want dividends, but do not want to rely on one or two companies doing all the work.

With that in mind, here are three excellent ASX ETFs that could be worth considering for passive income.

Vanguard Australian Shares High Yield ETF (ASX: VHY)

The Vanguard Australian Shares High Yield ETF could be a simple option for investors wanting passive income from Australian shares.

This fund focuses on shares listed on the local market that are expected to provide higher dividend yields than the broader Australian share market.

That naturally gives it exposure to some of the ASX’s more mature, cash-generating businesses. These may include companies from sectors such as financials, resources, telecommunications, consumer staples, and infrastructure.

Among its holdings are giants such as BHP Group Ltd (ASX: BHP), Commonwealth Bank of Australia (ASX: CBA), and Telstra Group Ltd (ASX: TLS).

Betashares Global Royalties ETF (ASX: ROYL)

The Betashares Global Royalties ETF offers a very different type of income exposure.

Rather than focusing on traditional dividend shares, this fund invests in companies that earn royalty income.

That can include royalties linked to areas such as music, intellectual property, pharmaceuticals, mining, energy, and other assets.

Royalty companies can earn a share of revenue from an asset without always carrying the same operating burden as the company producing, selling, or managing that asset directly.

This does not make them risk-free, but it can create attractive cash flow characteristics.

Betashares S&P 500 Yield Maximiser Complex ETF (ASX: UMAX)

A third ASX ETF to consider for passive income in September is the Betashares S&P 500 Yield Maximiser Complex ETF.

This fund gives investors exposure to a portfolio of US shares based on the S&P 500, while using an income-focused options strategy. This means it is able to produce more income than the underlying share portfolio would normally pay on its own.

That could be attractive for investors who want exposure to the US market but would also like regular distributions.

The trade-off is that this strategy can limit some of the upside when US shares rise strongly.

But for income-focused investors, UMAX could still be a useful option. It provides exposure to leading US companies while aiming to turn that portfolio into a stronger income generator.

The post 3 excellent ASX ETFs for passive income appeared first on The Motley Fool Australia.

More reading

• 3 ASX ETFs that are a perfect compliment to your superannuation
• How to earn $10,000 in passive income a month with these ASX dividend shares
• Term deposits are paying more than ever. Are ASX dividend shares still worth it?
• Could a September rate hike hurt your superannuation returns?
• VGS vs VHY: Which Vanguard ETF comes out on top?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended BetaShares S&P 500 Yield Maximiser Fund and Telstra Group. The Motley Fool Australia has recommended BHP Group and Vanguard Australian Shares High Yield ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.